Thymosin Alpha-1
28-amino acid thymic peptide (Zadaxin® precursor) studied for T-cell maturation, NK cell activation, and vaccine adjuvant effects. Approved pharmaceutical in 35+ countries for hepatitis B/C. Most clinically validated peptide in this category.
What Research Shows
Studied for TLR2/TLR9-mediated dendritic cell activation, T-cell maturation, NK cell cytotoxicity, and vaccine adjuvant effects. Studies measure CD4/CD8 ratio, NK cytotoxicity assay, and IFN-γ/IL-12 by ELISA. Clinical approval in 35+ countries provides exceptional human safety context versus research peptides.
Pros & Cons
- +Most clinically validated peptide in this guide — approved pharmaceutical with decades of post-marketing safety data
- +Twice-weekly subcutaneous dosing — manageable and predictable protocol
- +Strong mechanism: TLR2/TLR9 activation produces measurable immune response with dose-response characteristics
- +Human clinical data available for hepatitis and cancer populations — real-world safety context
- +Relatively affordable compared to other peptide categories
- +Used as a vaccine adjuvant in clinical studies — immune-specific, not broadly immunostimulatory
- −Hard to source in EU — most vendors list Thymosin Alpha-1 as "contact for availability" with no listed price
- −Immunostimulatory peptides can worsen autoimmune conditions — significant contraindication for autoimmune diseases
- −Most human clinical data comes from disease populations (hepatitis, cancer) — healthy-subject extrapolation is limited
- −Subjective effects are subtle — no acute sensation to gauge efficacy; results require immune panel testing
- −Not approved by FDA or EMA; Zadaxin® is not available in Western pharmacies without specific import
- −Thymosin Alpha-1 vs. Thymosin Beta-4 (TB-500) confusion is common — they are completely different compounds
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary significantly.
CD4/CD8 ratio changes and NK cell activity increases are measurable within 1–2 weeks in immunosuppressed animal models. Clinical hepatitis trials show viral load reductions at 4–8 weeks. Subjective effects are typically not noticeable — efficacy requires laboratory testing (immune panel, lymphocyte subsets).
What People Research This For
Practical Questions
How is Thymosin Alpha-1 different from Thymosin Beta-4 (TB-500)?
Despite both being called "thymosin," they are completely different molecules with different functions. Thymosin Alpha-1 is secreted exclusively by thymic epithelial cells and modulates the immune system — specifically T-cell development and activation. Thymosin Beta-4 (TB-500) is present in virtually every cell of the body and is primarily involved in actin cytoskeletal dynamics, tissue repair, and angiogenesis. They do not share mechanism, structure, or biological target.
Should I avoid Thymosin Alpha-1 if I have an autoimmune condition?
Yes — this is a significant caution. Thymosin Alpha-1 stimulates the immune system. If your immune system is already attacking your own tissues (as in rheumatoid arthritis, lupus, MS, or similar conditions), further immune stimulation could worsen symptoms. This is a conversation to have with a physician familiar with immunology before considering any immune-modulating compound.
Where to Buy Thymosin Alpha-1 in Canada
Thymosin Alpha-1 has limited Canadian vendor availability as of March 2026. Most Canadian vendors do not stock this compound routinely.
Contact vendors directly to check current stock, or see our full Canadian vendor comparison for contact details.